Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTPN11_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTPN11_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTPN11_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTPN11_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTPN11_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003350018 | Skin | AK | carbohydrate homeostasis | 45/1910 | 259/18723 | 2.60e-04 | 2.82e-03 | 45 |
GO:00603254 | Skin | AK | face morphogenesis | 10/1910 | 28/18723 | 2.78e-04 | 2.94e-03 | 10 |
GO:005087016 | Skin | AK | positive regulation of T cell activation | 39/1910 | 216/18723 | 2.94e-04 | 3.06e-03 | 39 |
GO:00100017 | Skin | AK | glial cell differentiation | 40/1910 | 225/18723 | 3.45e-04 | 3.47e-03 | 40 |
GO:00480134 | Skin | AK | ephrin receptor signaling pathway | 14/1910 | 51/18723 | 4.29e-04 | 4.05e-03 | 14 |
GO:00028319 | Skin | AK | regulation of response to biotic stimulus | 53/1910 | 327/18723 | 4.63e-04 | 4.31e-03 | 53 |
GO:190303917 | Skin | AK | positive regulation of leukocyte cell-cell adhesion | 41/1910 | 239/18723 | 6.22e-04 | 5.45e-03 | 41 |
GO:00336276 | Skin | AK | cell adhesion mediated by integrin | 17/1910 | 72/18723 | 7.51e-04 | 6.32e-03 | 17 |
GO:19019884 | Skin | AK | negative regulation of cell cycle phase transition | 42/1910 | 249/18723 | 7.65e-04 | 6.39e-03 | 42 |
GO:000975517 | Skin | AK | hormone-mediated signaling pathway | 34/1910 | 190/18723 | 8.18e-04 | 6.80e-03 | 34 |
GO:00101712 | Skin | AK | body morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:00603233 | Skin | AK | head morphogenesis | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
GO:00487084 | Skin | AK | astrocyte differentiation | 18/1910 | 81/18723 | 1.14e-03 | 8.81e-03 | 18 |
GO:00603243 | Skin | AK | face development | 12/1910 | 44/18723 | 1.16e-03 | 8.88e-03 | 12 |
GO:000828610 | Skin | AK | insulin receptor signaling pathway | 23/1910 | 116/18723 | 1.36e-03 | 1.01e-02 | 23 |
GO:003286819 | Skin | AK | response to insulin | 43/1910 | 264/18723 | 1.37e-03 | 1.02e-02 | 43 |
GO:003461425 | Skin | AK | cellular response to reactive oxygen species | 28/1910 | 155/18723 | 1.95e-03 | 1.32e-02 | 28 |
GO:000181917 | Skin | AK | positive regulation of cytokine production | 67/1910 | 467/18723 | 2.59e-03 | 1.67e-02 | 67 |
GO:00000776 | Skin | AK | DNA damage checkpoint | 22/1910 | 115/18723 | 2.74e-03 | 1.74e-02 | 22 |
GO:00614483 | Skin | AK | connective tissue development | 40/1910 | 252/18723 | 3.17e-03 | 1.95e-02 | 40 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0512018 | Esophagus | ESCC | Epithelial cell signaling in Helicobacter pylori infection | 52/4205 | 70/8465 | 2.17e-05 | 1.07e-04 | 5.47e-05 | 52 |
hsa0521118 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa052356 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0512019 | Esophagus | ESCC | Epithelial cell signaling in Helicobacter pylori infection | 52/4205 | 70/8465 | 2.17e-05 | 1.07e-04 | 5.47e-05 | 52 |
hsa0521119 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | II-B08 | | 20170098 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | U0126 | | 17942397 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | 4-HYDRAZINYLBENZENESULFONIC ACID | CHEMBL510966 | 19007293 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | cryptotanshinone | CRYPTOTANSHINONE | 23957426 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | PLX4720 | PLX-4720 | 26351322 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | MESO-2,3-DIMERCAPTOSUCCINIC ACID | CHEMBL28721 | |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | OLTIPRAZ | OLTIPRAZ | 20655236 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | Refametinib | REFAMETINIB | |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | N/A | | 19047918,21901340 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | TNO155 | | |